{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:36:30Z","timestamp":1791466590037,"version":"4.3.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Biologics for Children with Rheumatic Diseases"},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["20747"],"award-info":[{"award-number":["20747"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC773\/III\/CC\/101350"],"award-info":[{"award-number":["BRC773\/III\/CC\/101350"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21593"],"award-info":[{"award-number":["21593"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["20164"],"award-info":[{"award-number":["20164"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Clinicians concerned about long-term safety of biologics in JIA may consider tapering or stopping treatment once remission is achieved despite uncertainty in maintaining drug-free remission. This analysis aims to (i) calculate how many patients with JIA stop biologics for remission, (ii) calculate how many later re-start therapy and after how long, and (iii) identify factors associated with re-starting biologics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients starting biologics between 1 January 2010 and 7 September 2021 in the UK JIA Biologics Register were included. Patients stopping biologics for physician-reported remission, those re-starting biologics and factors associated with re-starting, were identified. Multiple imputation accounted for missing data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 1451 patients with median follow-up of 2.7\u2009years (IQR 1.4, 4.0), 269 (19%) stopped biologics for remission after a median of 2.2\u2009years (IQR 1.7, 3.0). Of those with follow-up data (N = 220), 118 (54%) later re-started therapy after a median of 4.7\u2009months, with 84% re-starting the same biologic. Patients on any-line tocilizumab (prior to stopping) were less likely to re-start biologics (vs etanercept; odds ratio [OR] 0.3; 95% CI: 0.2, 0.7), while those with a longer disease duration prior to biologics (OR 1.1 per year increase; 95% CI: 1.0, 1.2) or prior uveitis were more likely to re-start biologics (OR 2.5; 95% CI: 1.3, 4.9).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This analysis identified factors associated with successful cessation of biologics for remission in JIA as absence of uveitis, prior treatment with tocilizumab and starting biologics earlier in the disease course. Further research is needed to guide clinical recommendations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac463","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:58:16Z","timestamp":1663203496000},"page":"1926-1935","source":"Crossref","is-referenced-by-count":19,"title":["Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-1575","authenticated-orcid":false,"given":"Lianne","family":"Kearsley-Fleet","sequence":"first","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre , Manchester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Baildam","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Alder Hey Children\u2019s NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-9911","authenticated-orcid":false,"given":"Michael W","family":"Beresford","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Alder Hey Children\u2019s NHS Foundation Trust"},{"name":"Institute of Life Course and Medical Specialities, University of Liverpool , Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Douglas","sequence":"additional","affiliation":[{"name":"Scottish Network for Arthritis in Children (SNAC) , Edinburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E","family":"Foster","sequence":"additional","affiliation":[{"name":"Population and Health Institute, Newcastle University , Newcastle upon Tyne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taunton R","family":"Southwood","sequence":"additional","affiliation":[{"name":"Institute of Child Health Department, University of Birmingham , Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre , Manchester"},{"name":"National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8911-4113","authenticated-orcid":false,"given":"Coziana","family":"Ciurtin","sequence":"additional","affiliation":[{"name":"Centre for Adolescent Rheumatology, Division of Medicine, University College London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"2023050208171437500_keac463-B1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.semarthrit.2016.06.001","article-title":"Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): analysis from the UK Childhood Arthritis Prospective Study (CAPS)","volume":"46","author":"Davies","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2023050208171437500_keac463-B2","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/art.39197","article-title":"Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"67","author":"Davies","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023050208171437500_keac463-B3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2017-212613","article-title":"Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors","volume":"77","author":"Beukelman","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023050208171437500_keac463-B4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/rheumatology\/keu457","article-title":"Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting","volume":"54","author":"Tarkiainen","year":"2015","journal-title":"Rheumatology"},{"key":"2023050208171437500_keac463-B5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40272-019-00362-6","article-title":"Treatment withdrawal following remission in Juvenile Idiopathic Arthritis: a systematic review of the literature","volume":"21","author":"Halyabar","year":"2019","journal-title":"Pediatric Drugs"},{"key":"2023050208171437500_keac463-B6","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/kev429","article-title":"Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers","volume":"55","author":"Kearsley-Fleet","year":"2016","journal-title":"Rheumatology"},{"key":"2023050208171437500_keac463-B7","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2023050208171437500_keac463-B8","doi-asserted-by":"crossref","first-page":"h3868","DOI":"10.1136\/bmj.h3868","article-title":"How to develop a more accurate risk prediction model when there are few events","volume":"351","author":"Pavlou","year":"2015","journal-title":"BMJ"},{"key":"2023050208171437500_keac463-B9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023050208171437500_keac463-B10","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"2023050208171437500_keac463-B11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"2023050208171437500_keac463-B12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/kev434","article-title":"Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"55","author":"Kearsley-Fleet","year":"2016","journal-title":"Rheumatology"},{"key":"2023050208171437500_keac463-B13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/rheumatology\/ket490","article-title":"Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis","volume":"53","author":"Geikowski","year":"2014","journal-title":"Rheumatology"},{"key":"2023050208171437500_keac463-B14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3899\/jrheum.120842","article-title":"Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept","volume":"40","author":"Solari","year":"2013","journal-title":"J Rheumatol"},{"key":"2023050208171437500_keac463-B15","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","article-title":"Factors associated with treatment response to etanercept in juvenile idiopathic arthritis","volume":"306","author":"Otten","year":"2011","journal-title":"JAMA"},{"key":"2023050208171437500_keac463-B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12969-017-0178-9","article-title":"Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children\u2019s Health, Russia","volume":"15","author":"Alexeeva","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2023050208171437500_keac463-B17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2023050208171437500_keac463-B18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-021-02492-0","article-title":"Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis","volume":"23","author":"Klotsche","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023050208171437500_keac463-B19","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.40509","article-title":"Risk, timing, and predictors of disease flare after discontinuation of anti-tumor necrosis factor therapy in children with polyarticular forms of juvenile idiopathic arthritis with clinically inactive disease","volume":"70","author":"Lovell","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2023050208171437500_keac463-B20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","article-title":"The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort","volume":"75","author":"Guzman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023050208171437500_keac463-B21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3899\/jrheum.161078","article-title":"Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the childhood arthritis and rheumatology research alliance","volume":"44","author":"Horton","year":"2017","journal-title":"J Rheumatol"},{"key":"2023050208171437500_keac463-B22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3899\/jrheum.110745","article-title":"Parent and child acceptable symptom state in juvenile idiopathic arthritis","volume":"39","author":"Filocamo","year":"2012","journal-title":"J Rheumatol"},{"key":"2023050208171437500_keac463-B23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.23916","article-title":"Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis","volume":"59","author":"Magni-Manzoni","year":"2008","journal-title":"Arthritis Care Res"},{"key":"2023050208171437500_keac463-B24","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","article-title":"Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score","volume":"64","author":"Consolaro","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023050208171437500_keac463-B25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-015-0723-1","article-title":"MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis","volume":"17","author":"Anink","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2023050208171437500_keac463-B26","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.semarthrit.2021.07.017","article-title":"Consensus-driven conceptual development of a standardized whole body-MRI scoring system for assessment of disease activity in juvenile idiopathic arthritis: MRI in JIA OMERACT working group","volume":"51","author":"Panwar","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2023050208171437500_keac463-B27","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1016\/j.ultrasmedbio.2021.05.003","article-title":"Correlation of ultrasound synovitis joint count with disease activity and its longitudinal variation with treatment response to etanercept in rheumatoid arthritis","volume":"47","author":"Wang","year":"2021","journal-title":"Ultrasound Med Biol"},{"key":"2023050208171437500_keac463-B28","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2021-222029","article-title":"Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial","volume":"81","author":"Gerss","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023050208171437500_keac463-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20340","article-title":"The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation","volume":"20","author":"Shepherd","year":"2016","journal-title":"Health Technol Assess"},{"key":"2023050208171437500_keac463-B30","author":"Prescribing and Medicines Team NHS Digital","year":"2018"},{"key":"2023050208171437500_keac463-B31","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1007\/s12325-019-00986-7","article-title":"Cost-effectiveness of early treatment with originator biologics or their biosimilars after methotrexate failure in patients with established rheumatoid arthritis","volume":"36","author":"Patel","year":"2019","journal-title":"Adv Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac463\/45812901\/keac463.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/5\/1926\/50120830\/keac463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/5\/1926\/50120830\/keac463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T08:22:29Z","timestamp":1683015749000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/5\/1926\/6696753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,15]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac463","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,9,15]]}}}